| Similar Articles |
|---|
 |
The Motley Fool
June 9, 2011
Brian Orelli |
XOMA Breaks Bad News to Investors XOMA 052 continues to be a disaster in diabetes.   |
The Motley Fool
July 8, 2008
Brian Lawler |
Blockbuster Drugs Bound for Extinction? One of the biggest classes of prescription drugs, those for diabetes treatments, faces tougher FDA standards. |
The Motley Fool
September 2, 2011
Brian Orelli |
Delcath Wants a Do-Over You'd think a drug failing to show an effect would be the worst thing that could happen to a biotech investor, but mixed results are actually much worse. |
The Motley Fool
August 15, 2011
Jim Royal |
6 Wild Bets on Biotech Riches The most interesting biotech tickers. |
Managed Care
June 2007 |
Seventy Percent Surge In Diabetes Spending Spending on endocrine and diabetes therapies could surge nearly 70% in the next two years, according to research. Diabetes treatments were the second leading contributor in total dollars to prescription drug spending growth in 2006. |
Pharmaceutical Executive
October 1, 2005 |
Changing Diabetes An interview with Novo Nordisk's president of U.S. operations Martin Soeters on how a nation that leads the world in diabetes research does such a poor job of treating it. Here, he offers some solutions. |
AskMen.com
April 29, 2001
Joshua Levine |
Do You Have Diabetes? Diabetes is not contagious; people cannot "catch" it from one another. However, certain factors can increase one's risk of developing the disease... |
The Motley Fool
December 15, 2003
W.D. Crotty |
Millennium Celebration Millennium took just four and a half years to push Velcade from first human dose to FDA approval, and the company has financial muscle most biotechnology companies only dream about. |
Nursing Management
January 2012
Lawrence et al. |
Type 2 Diabetes: Growing to Epic Proportions Affecting all age groups and all aspects of a person's life, diabetes is a major public health issue worldwide, requiring lifelong behavioral and lifestyle changes and support. |
The Motley Fool
December 7, 2009
Rick Aristotle Munarriz |
4 More Stocks on Wall Street's Dollar Menu Four quarters for a public company? Here are four stocks that mean it. |
American Family Physician
November 1, 2000 |
Diabetes: How Do I Know if I Have it? Diabetes is a disease that occurs when your body doesn't make enough of a hormone called insulin, or if your body doesn't use insulin the right way. If left untreated, it may result in blindness, heart attacks, strokes, kidney failure and amputations... |
The Motley Fool
July 20, 2005
Stephen D. Simpson |
Two Ways to Play Roche Trying to track Roche is a pain, so investors might want to think about Genentech instead. |
The Motley Fool
June 24, 2009
Rick Aristotle Munarriz |
5 More Stocks on Wall Street's Dollar Menu There are still many recognized stocks trading for less than $1 a share. Take a look at five. |
The Motley Fool
February 10, 2004
David Nierengarten |
The Psoriasis Wars The pharma heavies are battling for the chronic skin disease's market. |
The Motley Fool
January 19, 2012
Sean Williams |
No Vacancy: Workers Need Not Apply to This Sector Pharmaceutical and biotech layoffs are kicking into high gear. |
Managed Care
May 2006
Frank Diamond |
It's Hard To Not Take Diabetes Personally The costs are of managing diabetes are ballooning and incidence is up and going to go higher. |
